PTX -022 Palvella Therapeutics, Inc.  
Protocol PALV-06 27June2022 
Amendment #4 
Confidential A MULTICENTER, PHASE 2, OPEN -LABEL STUDY EVALUATING THE SAFETY 
AND EFFICACY OF SIROLIMUS 3.9% TOPICAL GEL (PTX -022) IN THE 
TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS   
Protocol Number: PALV-06 
Compound Number PTX -022 
Sponsor Name: Palvella Therapeutics, Inc.  
Legal Registered Address : 125 Strafford Ave, Suite 360 
Wayne, PA 19087 
Regulatory Agency Identifying 
Number(s): 
A
pproval Date 27June2022 
